
We’re excited to share more about Indonesia’s NHI system! It’s incredible to see how they implemented universal healthcare and overcame unique challenges.
These insights are based on a recent interview by Alec Hogg and Ali Ghufron Mukti but through the lens of health economics and outcomes research, and access to medicines.
Of course, no system is perfect, and Indonesia’s NHI journey reminds us of the importance of constant vigilance to address challenges like funding and corruption issues.
Thank you for sharing these important lessons!
Recent Posts
Key Strategies in Neonatal Infection Management: Insights from NICE Guideline NG195
The NICE guideline NG195 establishes a structured framework for neonatal infection management in newborns up to 28 days corrected gestational age, treating at-risk pregnant individuals, and managing suspected or confirmed infections in neonates. It emphasizes timely recognition to avoid delays, j...
Strengthening Supply Chains: The EU Critical Medicines Act
The European Medicines Agency (EMA) has welcomed the provisional political agreement on the EU Critical Medicines Act, an initiative designed to enhance the availability, production, and supply of critical medicines throughout the European Union. This agreement represents a key a...
Marstacimab Cost-Effectiveness Analysis in Hemophilia Treatment: A Portuguese Assessment
The public assessment report for Hympavzi (marstacimab) in Portugal concludes that the product offers no added therapeutic value relative to recombinant factor VIII concentrates and emicizumab in patients aged 12 years and older weighing at least 35 kg with severe hemophilia A without factor VIII...